Moderna (MRNA)
Technical, fundamental, and sentiment analysis with recent related videos.
MRNA rates Neutral overall. The fundamental read is neutral: the company passes 1 of 9 quality tests on the Piotroski F-Score; balance sheet is in the Safe zone (Altman Z = 13.60); revenue is declining about 52.3% per year. The technical picture is bullish: price is 143.5% above the 200-day moving average; 16.9% above the 50-day; the 50/200 relationship is in a Golden cross. Sentiment is bearish (composite 28/100), based on 4 news articles, 1 TV segment, and 7 qualified videos from recent coverage.
Revenue 3-year avg -52.3%. Net income 3-year avg N/A.
Price vs 20DMA -4.9%. RSI 50.2. Bollinger state: Inside Bands.
Composite score 28/100 from the AI judge, based on 4 news items, 1 television segments, and 7 videos.
Latest Market Read
Moderna’s three badges split. Fundamentals sit Neutral even though revenue averaged -52.3 percent per year over three years and annual net income is mixed; the negative revenue trend is real but not weighted into a Bearish label. Technical is Bullish: the Relative Strength Index (RSI), a momentum reading, is 50.2, price remains above the 200-day average with a Golden cross, though the stock trades about 4.9 percent below its 20-day moving average and inside its Bollinger Bands. Sentiment is Bearish at 28/100. Those opposing signals combine into an overall Neutral rating.
Recent news: Global Database of Events, Language, and Tone (GDELT) and Internet Archive TV coverage focused on Moderna’s Phase 3 INTerpath-001 readout, where intismeran plus Keytruda cut melanoma recurrence risk by 42% and improved distant metastasis‑free survival with acceptance to the New England Journal of Medicine (NEJM). A leaked data report sparked a roughly 20% selloff, and videos and TV segments emphasized the market plunge, debate over whether future sales are already priced in, and execution concerns despite clinicians’ praise.